|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
AstraZeneca PLC (AZN) Establishes First Russian Biobank
1/17/2013 7:34:27 AM
AstraZeneca is expanding its biotechnology operations in Russia, through the establishment of the country’s first biobank and a clinical research center in St. Petersburg. The new biobank will be officially launched in the second half of 2013 and will be based at the V.A. Almazov Federal Center for Heart, Blood and Endocrinology, one of the leading Russian scientific medical institutions. The biobank will focus on storing samples for use in biomedical research. The project also involves the establishment of a network of scientific laboratories and research organizations throughout Russia. AstraZeneca hopes the new biobank will create conditions for more active development of drugs for the treatment of cardiovascular diseases, rheumatology, and oncology diseases. In addition, it will speed to development of drugs against a number of genetic diseases. According to Vitaly Prutsky, head of the Center for Bioinformatics and Predictive Medicine, AstraZeneca Russia, Russia’s leading medical research centers will be providing samples. The project will initially be funded through venture capital funding of more than $6 million. Other details of the project are not disclosed. Eugene Shlyakhto, professor and the director of the Almazov Center, commented: “The list of potential customers of the new biobank will be very broad, and will include many Russian, as well as foreign pharmaceutical, diagnostic and biotechnology companies.” Russian analysts believe that AstraZeneca’s new Russian project will be successful. Nikolai Nikitin, head of the Voronezh Children's Clinic, one of the leading Russian child health centers, says the demand for samples from the future biobank will be very high from domestic pharmaceutical companies as well as local clinics and hospitals. Nikitin says the project will help address the health care needs of the local population, which is experiencing a rise of chronic diseases and generally low overall health.
|
|
|
|
|
|
|
|
|
|
|